Drug Discovery

#Drug development #Drug discovery #Guide #Mouse models #Oncology #Preclinical investigations

Unlock the full potential of your preclinical oncology studies with a humanized mouse model

With an attrition rate of up to 95% for oncology drug development, it is evident that significant barriers still exist when it comes to translating preclinical investigation findings to in-human trials. Our Guide explores how humanized mouse models can help accelerate the successful development of novel, safe, and effective treatments… Read More

#Intelligence #Resources

Clinical research
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Roundtable: What will have most impact on drug discovery trends?

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News

mRNA
#Drug development #Elegen #Events #mRNA #mRNA-based vaccines #Webinar

Webinar: Where are the breakthroughs in mRNA?

Hosted by DDW and sponsored by Elegen, “Where are the breakthroughs in mRNA drug discovery and development?” will be free to attend on July 19 at 8AM PDT / 11AM EST / 4PM BST / 5PM CET. Join this free webinar to learn about the opportunities in mRNA drug discovery… Read More

Webinar date:
Brought to you by The Jackson Laboratory
#News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

New episode: DDW Highlights 19 June

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs,… Read More

#News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

This week in drug discovery (12-16 June)  

News round-up for 5-9 June by DDW Multimedia Editor Megan Thomas.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs, which is a common theme throughout this week’s news highlights, including an FDA approval for Pfizer, a NICE recommendation… Read More

#News

#Drug development #Drug discovery #Life science #Partnership #Pistoia Alliance

Pistoia Alliance announces Japanese R&D partnerships 

The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, has announced a new partnership with Matador Japan KK to enable pre-competitive collaboration in the Japanese market.   The Alliance and Matador share the vision that bringing together experts from diverse backgrounds… Read More

#News

Medical research
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Join our roundtable on drug discovery and development trends

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News

Cancer cell
#Cancer research #Chemotherapy #Drug development #National Institute for Health and Care Excellence (NICE) #Regulatory

Positive NICE recommendation for BRCAm ovarian cancer 

AstraZeneca UK announced that Lynparza (olaparib) is recommended by the National Institute for Health and Care Excellence (NICE) for maintenance treatment of BRCA-mutated relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who have had two or more courses of platinum-based chemotherapy.  BRCA1… Read More

#Editor's Choice #News #Regulatory #Trending News

#Drug discovery #Research #Research and development

Scientific SaaS platform to accelerate drug and materials development 

Revvity has launched its Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across R&D disciplines from drug discovery to specialty chemicals material development.   The new solution from Revvity Signals Software, the software and informatics arm of Revvity, is available worldwide. It integrates the… Read More

#News

CGTC Edinburgh lab
#Cell and gene therapy #Cell and Gene Therapy Catapult #CGT Catapult #Edinburgh BioQuarter #Lab technology

Cell and Gene Therapy Catapult opens new Scottish laboratories 

The Cell and Gene Therapy Catapult (CGT Catapult) has opened its facility in the Edinburgh BioQuarter, its first site in Scotland.   By opening these new laboratories, the CGT Catapult aims to provide expertise, resources and technology to help cell therapy developers improve their manufacturing processes and navigate… Read More

#News

Drug discovery
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Exclusive roundtable on drug discovery and development trends

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News

AI brain partnership
#AI #Drug discovery #Innovation #Mental health #Partnership

Partnership targets hard-to-diagnose mental health conditions 

Pangaea Data has been awarded a strategic partnership by the newly established Mental Health Research for Innovation Centre (M-RIC).   Pangaea is a provider of a novel artificial intelligence (AI)-driven product for characterising patients by automatically discovering clinical signatures for 4,000 hard-to-diagnose conditions in an evolving, privacy-preserving and… Read More

#News

#AI #ALS #BenevolentAI #Drug discovery

BenevolentAI progresses drug for the potential treatment of ALS 

BenevolentAI, developers of AI that accelerates biopharma discovery, has delivered BEN-34712, its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS).  BEN-34712 is an oral, potent and selective brain penetrant RARɑ𝛃 (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug… Read More

#News

Artificial intelligence
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Benchling #Cancer research #Drug discovery #Machine learning #Rare disease

Latest eBook: AI and drug development

The latest eBook by DDW is out now. This 28-page eBook, sponsored by Benchling, examines the ways in which artificial intelligence and machine learning are expediting drug discovery efforts. Download this exclusive eBook to learn more about: The latest advancements in artificial intelligence… Read More

#News

Lightbulb, ideas, innovation
#AI #Animal models #Animal testing #BioInnovation Institute #Data science #Drug discovery #Drug research #Microbiome #Regulatory

New podcast: Innovate to reinvent the future of drug discovery

This is the latest episode of the free DDW narrated podcast, “Innovating now to reinvent the future of drug discovery”. It covers three articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Predictive biomarkers in the… Read More

#News